A Critical Review of Momordica Charantia, Curcuma longa & Gymnema sylvestre Polyherbal Systems For Diabetes Management

Diabetes mellitus remains a major global health challenge, driving interest in polyherbal formulations as cost effective, multi target therapeutic options. Gymnema sylvestre, Curcuma longa, and Momordica charantia are widely used antidiabetic botanicals with complementary mechanisms of action. This narrative review critically examines the phytochemistry, pharmacological evidence, and formulation evaluation strategies relevant to developing polyherbal antidiabetic capsules containing these three plants. Key bioactive constituents, including gymnemic acids, curcuminoids, and charantin together with cucurbitanes, modulate glucose homeostasis by enhancing insulin secretion and sensitivity, inhibiting carbohydrate hydrolyzing enzymes, and acting through antioxidant and anti inflammatory pathways. Preclinical investigations consistently report hypoglycaemic and organ protective effects, while clinical studies support their adjunctive use in type 2 diabetes, although extract standardization and dosing regimens vary considerably. Encapsulation improves patient compliance, protects labile herbal actives, and allows flexible dosing, but demands careful control of moisture, powder flow, content uniformity, and marker based standardization. Recommended quality assessments comprise weight variation, disintegration, dissolution, microbial limits, heavy metal testing, and stability studies supported by HPLC/HPTLC fingerprinting of marker compounds. Polyherbal capsules combining M. charantia, C. longa, and G. sylvestre are both scientifically rational and pharmaceutically viable, provided that rigorous standardization, quality control, and safety evaluation are implemented. Robust clinical trials and bioavailability studies are required to confirm therapeutic benefit and optimize dosing schedules.